Dr. Sulaiman Al Habib Medical Services Group posted a 3% profit rise in the first nine months of 2025 to SAR 1.75 billion, compared to SAR 1.70 billion in the prior-year period.
| Item | 9m 2024 | 9m 2025 | Change |
|---|---|---|---|
| Revenues | 8,071.59 | 10,005.45 | 24.0 % |
| Gross Income | 2,747.45 | 3,144.22 | 14.4 % |
| Operating Income | 1,732.13 | 1,936.50 | 11.8 % |
| Net Income | 1,701.52 | 1,750.31 | 2.9 % |
| Average Shares | 350.00 | 350.00 | - |
| Earnings Per Share before unusual items (Riyals) | 4.86 | 5.00 | 2.9 % |
| EPS (Riyal) | 4.86 | 5.00 | 2.9 % |
Revenues increased 23.96% to around SAR 10 billion in the nine-month period, compared to SAR 1.07 billion in the same period last year, owing to strong performance in the hospital and pharmacy segments.
Earnings before interest, taxes, depreciation, and amortization (EBITDA) increased by 19.99% to SAR 2.56 billion, up from SAR 2.14 billion in 9M 2024, with a profit margin of 25.63%.
| Item | Q3 2024 | Q3 2025 | Change |
|---|---|---|---|
| Revenues | 2,976.56 | 3,463.34 | 16.4 % |
| Gross Income | 992.10 | 1,049.93 | 5.8 % |
| Operating Income | 624.38 | 665.71 | 6.6 % |
| Net Income | 595.54 | 602.28 | 1.1 % |
| Average Shares | 350.00 | 350.00 | - |
| Earnings Per Share before unusual items (Riyal) | 1.70 | 1.72 | 1.1 % |
| EPS (Riyal) | 1.70 | 1.72 | 1.1 % |
| Item | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Revenues | 3,384.33 | 3,463.34 | 2.3 % |
| Gross Income | 1,065.98 | 1,049.93 | (1.5 %) |
| Operating Income | 644.87 | 665.71 | 3.2 % |
| Net Income | 591.02 | 602.28 | 1.9 % |
| Average Shares | 350.00 | 350.00 | - |
| Earnings Per Share before unusual items (Riyal) | 1.69 | 1.72 | 1.9 % |
| EPS (Riyal) | 1.69 | 1.72 | 1.9 % |
Sulaiman Al Habib’s Q3 2025 net profit grew 1% to SAR 602.3 million, from SAR 595.54 million in Q3 2024.
Compared to Q2 2025, net earnings rose 1.9% from SAR 591.02 million.
Shareholders’ equity, after minority interest, reached SAR 7.68 billion as of Sept. 30, 2025, up from SAR 6.99 billion a year earlier.
| Company | Estimated | Actual | Change |
|---|---|---|---|
| ACC | 20.43 | 65.50 | |
| YANSAB | 70.63 | 74.20 | |
| NADEC | 124.50 | 110.67 | |
| MODERN MILLS | 56.83 | 56.14 | |
| ZAIN KSA | 134.64 | 153.00 | |
| ALBILAD | 767.86 | 766.50 | |
| SULAIMAN ALHABIB | 622.50 | 602.28 | |
| SABIC AGRI-NUTRIENTS | 1,071.65 | 1,290.00 | |
| TADAWUL GROUP | 84.97 | 82.70 | |
| JAMJOOM PHARMA | 115.18 | 106.67 |
| Company | Estimated | Actual | Change |
|---|---|---|---|
| ACC | 20.43 | 65.50 | |
| YANSAB | 70.63 | 74.20 | |
| NADEC | 124.50 | 110.67 | |
| MODERN MILLS | 56.83 | 56.14 | |
| ZAIN KSA | 134.64 | 153.00 | |
| ALBILAD | 767.86 | 766.50 | |
| SULAIMAN ALHABIB | 622.50 | 602.28 | |
| SABIC AGRI-NUTRIENTS | 1,071.65 | 1,290.00 | |
| TADAWUL GROUP | 84.97 | 82.70 | |
| JAMJOOM PHARMA | 115.18 | 106.67 |
Be the first to comment
Argaam Investment Company has updated the Privacy Policy of its services and digital platforms. Know more about our Privacy Policy here.
Argaam uses cookies to personalize content, to provide social media features and analyze traffic, that we might also share with third parties. You consent to our cookies if you use this website

Comments Analysis: